Five Trends In Obesity Clinical Trials - Investigator Perspectives On What Matters In Obesity And GLP-1 Studies

Obesity and GLP-1 clinical trials are entering a more complex phase, where study success depends on more than enrollment speed. Long study durations, placebo arms, and easy access to commercial GLP-1s are making retention a central operational risk for sponsors. Stronger participant education, dietitian support, coordinator coaching, and flexible visit models can help keep participants engaged through study completion.

At the same time, trial designs are evolving to account for lean-mass considerations, maintenance dosing strategies, amylin analogs, and the growing documentation burden tied to prior GLP-1 exposure. Sponsors may need clearer pathways for medical-record collection, validated body-composition measures, functional endpoints, and proactive adverse-event education as obesity research continues to advance.

Lifestyle, psychosocial support, and real-world adherence behaviors also deserve closer attention, especially as obesity studies move toward longer-term maintenance goals. Access the full article to explore five investigator-informed trends shaping obesity and metabolic trial planning.